RenovoRx (NASDAQ:RNXT) Stock: Insider Ramtin Agah Buys 50,000 Shares

RenovoRx, Inc. (NASDAQ:RNXT – Get Free Report) CMO Ramtin Agah acquired 50,000 shares of the business’s stock in a transaction on Monday, November 16th. The shares were bought at an average price of $0.93 per share, for a total transaction of $46,500.00. Following the acquisition, the chief marketing officer owned 848,460 shares in the company, valued at approximately $789,067.80. This trade represents a 6.26% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

RenovoRx Trading Up 7.7%

Shares of RNXT opened at $1.12 on Thursday. The company has a 50-day moving average of $1.38 and a two-hundred day moving average of $1.11. RenovoRx, Inc. has a one year low of $0.73 and a one year high of $2.59.

RenovoRx (NASDAQ:RNXT – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). RenovoRx had a negative net margin of 469.02% and a negative return on equity of 133.49%. The firm had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.06 million. Equities analysts forecast that RenovoRx, Inc. will post -0.28 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Wall Street Zen lowered RenovoRx from a “hold” rating to a “sell” rating in a research report on Monday, November 9th. Weiss Ratings upgraded shares of RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, RenovoRx presently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

Get Our Latest Stock Analysis on RenovoRx

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of RNXT. Cetera Investment Advisers lifted its holdings in shares of RenovoRx by 205.1% during the 3rd quarter. Cetera Investment Advisers now owns 57,976 shares of the company’s stock valued at $90,000 after buying an additional 38,976 shares during the last quarter. T3 Companies LLC acquired a new position in RenovoRx in the third quarter worth approximately $151,000. Finally, State Street Corp raised its position in RenovoRx by 501.6% during the third quarter. State Street Corp now owns 314,636 shares of the company’s stock valued at $491,000 after acquiring an additional 262,332 shares in the last quarter. 3.10% of the stock is owned by institutional investors and hedge funds.

RenovoRx Company Profile

(Get Free Report)

RenovoRx, Inc. is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its approach is designed to deliver therapy directly to targeted tissue through the arteries that supply it, with the goal of limiting exposure to the rest of the body. The company’s platform includes RenovoCath, a catheter cleared by the U.S. Food and Drug Administration for the localized infusion of therapeutic agents. RenovoRx is also evaluating RenovoGem, a combination of its delivery approach and the chemotherapy drug gemcitabine, for patients with locally advanced pancreatic cancer.

Featured Articles

Insider Buying and Selling by Quarter for RenovoRx (NASDAQ:RNXT)

Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.